(function(){var loadHandler=window['sl_{D3EC29EB-8C83-4699-A807-A78E58DCD4CF}'];loadHandler&&loadHandler(2, '<div id="spr0_5da6315f"><div id="spr1_5da6315f" class="kern slide"><img id="img4_5da6315f" src="data/img1.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_5da6315f" class="kern slide"><img id="img0_5da6315f" src="data/img6.png" width="721.48" height="100.8" alt="" style="left:-1.48px;"/><div id="svg1_5da6315f" style="left:-1.48px;top:99.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#c76c02" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><div id="svg2_5da6315f" style="left:-1.48px;top:0.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#2e3546" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><img id="img1_5da6315f" src="data/img7.png" width="721.48" height="43.101" alt="" style="top:496.899px;"/><div id="spr3_5da6315f" style="left:657.715px;top:499.855px;"><img id="img2_5da6315f" src="data/img8.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr4_5da6315f" style="left:-1.48px;top:4.123px;"><div style="width:0px;"><span id="txt0_5da6315f" data-width="654.363281" style="left:32.75px;top:5.272px;">Additional Benefit of PCSK9 Inhibition in High-</span></div><div style="width:0px;"><span id="txt1_5da6315f" data-width="562.710938" style="left:78.625px;top:48.472px;">Risk Patients after Myocardial Infarction</span></div></div><div id="spr5_5da6315f" style="left:38.424px;top:144.776px;"><img id="img3_5da6315f" src="data/img9.png" width="654" height="285" alt="" style="left:0.228px;top:-0.2px;"/></div><div id="spr6_5da6315f" style="left:30.261px;top:106.079px;"><div style="width:0px;"><span id="txt2_5da6315f" data-width="266.656250" style="left:190.801px;top:4.901px;">A FOURIER Subanalysis</span></div></div><div id="spr7_5da6315f" style="left:44.625px;top:434.443px;"><div style="width:0px;"><span id="txt3_5da6315f" class="nokern" data-width="610.266357" style="left:7.2px;top:4.179px;">Primary endpoint: composite of CV death, MI, stroke, coronary revascularization, or hospitalization for unstable angina; Recent MI: within the past 2 years; multi-</span></div><div style="width:0px;"><span id="txt4_5da6315f" class="nokern" data-width="192.942627" style="left:7.2px;top:16.779px;">vessel disease: ≥40% stenosis in ≥2 large vessels</span></div><div style="width:0px;"><span id="txt5_5da6315f" class="nokern" data-width="617.382568" style="left:7.2px;top:29.379px;">PCSK9: proprotein convertase subtilisin-kexin type 9; FOURIER: Further cardiovascular Outcomes Research with PCSK9 Inhibition in patients with Elevated Risk;</span></div><div style="width:0px;"><span id="txt6_5da6315f" class="nokern" data-width="95.715088" style="left:7.2px;top:41.979px;">MI: myocardial infarction;</span></div></div><div id="spr8_5da6315f" style="left:17.663px;top:508.15px;"><div style="width:0px;"><span id="txt7_5da6315f" class="nokern relpos" data-width="31.187988" style="left:7.2px;top:4.096px;">Sabatine </span><span id="txt8_5da6315f" class="nokern relpos" data-width="21.057188" style="left:7.195px;top:4.162px;">et al. </span><span id="txt9_5da6315f" class="nokern relpos" data-width="53.332031" style="left:7.19px;top:4.096px;">Circulation 2018</span></div></div></div></div>');})();